Asthma and COPD - Get SMART

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-11-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

There is a positive outlook for the respiratory market over the next five years, which will experience a sustained period of growth driven by the expansion of sales in existing classes, the launch of major new products, and the results from several landmark studies. However, the patent expiries of two leading products, Singulair and Seretide, will see growth flatten from the turn of the decade.


Scope

  • Indication based forecasts for asthma/COPD products, with additional coverage of antileukotrienes sales in allergic rhinitis
  • Assessment of country-specific drivers and resistors likely to impact the market
  • Future market outlook for individual products taking into account key market events in particular, patent expiries, and competitor launches
  • Market overview by geographical area, with value analysis of clinical and commercial factors underlying product performance


    • Report Highlights
    Global asthma/COPD sales should grow to $23 billion by 2014, with inhaled corticosteroid/long-acting bronchodilator combinations set to be the leading class by value in 2014, followed by leukotriene antagonists, and anticholinergics.

    AstraZeneca's Symbicort should become the top-selling brand in the global market, driven by the approval of Symbicort Maintenance and Reliever therapy (SMART) in the EU, the launch of Symbicort in the US market, and the impact of generic competition on Advair/Seretide sales.

    Four new launches are expected within the next five years, the most significant being Symbicort in the US and the launch of novel ICS/LABA combination products which will need a strong differentiation profile, based on improved safety, flexible dosing, or once-daily dosing to compete with Advair/Seretide and Symbicort.


    Reasons to Purchase

  • Identify key environmental opportunities and threats that will impact the use and uptake of new and existing products
  • Quantify the future size and scope of the asthma/COPD market and predict the future performance of key compounds
  • Capitalize on clinical unmet needs in the market, either through the lifecycle management of marketed drugs or new product development

    • Table of Contents

    Other users found this report page using the following search terms: asthma copd emphysema respiratory bronchitis airway copd symbicort asthma smart seretide market advair price regime launch

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.